Article

SH003 enhances the anti-cancer effects of Dabrafenib on lung cancer harboring BRAF G469A mutation by inhibiting the MAPK signaling pathway

2023-12-04

Abstract excerpt

<title>Abstract</title> <p>BRAF mutations are relatively uncommon in lung cancer. However, the majority of therapies targeting BRAF mutations have been developed exclusively for lung cancer patients with V600E mutations, limiting their effectiveness in treating tumors with the non-V600E BRAF mutations. As a result, there is a need to explore effective therapeutic strategies for lung cancer patients carrying non-V...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a3018d49-d4b8-56ae-83b9-dc0b6ac827f4
DOI: 10.21203/rs.3.rs-3623622/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

SH003 enhances the anti-cancer effects of Dabrafenib on lung cancer harboring BRAF G469A mutation by inhibiting the MAPK signaling pathwayDOI 10.21203/rs.3.rs-3623622/v1Read

SH003 Enhances the Anti-cancer Effects of Dabrafenib on Lung Cancer Harboring BRAF G469A Mutation by Inhibiting the MAPK Signaling Pathway.Semantic proximity Read

Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.Semantic proximity Read

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.Semantic proximity Read

Dabrafenib and trametinib for the treatment of non-small cell lung cancer.Semantic proximity Read

[Strategic Exploration of Targeted Therapy for BRAF Non-V600E Mutant Lung Cancer].Semantic proximity Read

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.Semantic proximity Read

BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.Semantic proximity Read

Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus TrametinibSemantic proximity Read

Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation.Semantic proximity Read

Dabrafenib-trametinib in BRAF V600-mutated non-small-cell lung cancer: a single center real world experience.Semantic proximity Read

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancerSemantic proximity Read

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations.Semantic proximity Read